Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SARS-CoV-2 Inactivated Vaccine · 1 trial · 1 indication
Incidence rate of adverse reactions occured from the beginning of the vaccination to 28 days after the second dose.
| Arm | Type | Description |
|---|---|---|
| Experimental Group | EXPERIMENTAL | Participant will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine . Vaccine will given by intramuscular injection on day 0 and day 28. |
| Control Group | PLACEBO_COMPARATOR | Placebo will receive two doses of placebo. The placebo will given by intramuscular injection on day 0 and day 28. |
| Name | Type | Description |
|---|---|---|
| SARS-CoV-2 Inactivated Vaccine | BIOLOGICAL | 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection |
| Placebo | BIOLOGICAL | aluminium hydroxide solution only |
Inclusion Criteria: * Healthy children and adolescents aged 3-17 years; * The subjects and/or guardians can understand and voluntarily sign the informed consent form (For subjects aged 8-17 years, both subjects and guardians need to sign the informed consent form); * Proven legal identity. Exclusi...
SARS-CoV-2 Inactivated Vaccine is an investigational vaccine being studied for the prevention of COVID-19. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The vaccine is designed to elicit an immune response against the SARS-CoV-2 virus, which causes COVID-19.
SARS-CoV-2 Inactivated Vaccine is being developed by Sinovac Biotech, Ltd, a biopharmaceutical company traded on the stock exchange under the ticker symbol SVA. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in the target population.
SARS-CoV-2 Inactivated Vaccine is currently in Phase 2 clinical development. It is an investigational vaccine and has not yet received regulatory approval. The ongoing clinical program aims to assess the vaccine's safety and immune response in children and adolescents aged 3 years and older.
SARS-CoV-2 Inactivated Vaccine has one completed clinical trial registered under NCT04884685, titled 'Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents'. This Phase 2, randomized, double-blind, placebo-controlled trial enrolled 500 participants in China to evaluate the vaccine's safety.
Yes, SARS-CoV-2 Inactivated Vaccine is also known as CoronaVac. The clinical trial NCT04884685 refers to the vaccine as CoronaVac, indicating that these names refer to the same investigational vaccine being developed by Sinovac Biotech for the prevention of COVID-19.